Growth Metrics

Akebia Therapeutics (AKBA) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to $1.5 million.

  • Akebia Therapeutics' Depreciation & Amortization (CF) fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • As of FY2024, Akebia Therapeutics' Depreciation & Amortization (CF) stood at $1.5 million, which was down 7.76% from $1.6 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Depreciation & Amortization (CF) peaked at $2.1 million during FY2020, and registered a low of $1.5 million during FY2024.
  • For the 3-year period, Akebia Therapeutics' Depreciation & Amortization (CF) averaged around $1.6 million, with its median value being $1.6 million (2023).
  • Data for Akebia Therapeutics' Depreciation & Amortization (CF) shows a maximum YoY decreased of 14.17% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million in 2020, then fell by 7.13% to $1.9 million in 2021, then fell by 14.17% to $1.7 million in 2022, then fell by 4.17% to $1.6 million in 2023, then dropped by 7.76% to $1.5 million in 2024.